AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 161 min read$TENX

Giordano Christopher Thomas purchased $20K of TENX

Giordano Christopher Thomas (CEO) purchased 10,850 shares of TENAX THERAPEUTICS, INC. (TENX) at an average of $1.85 ($1.82–$1.88) across 2 trades over 2026-09-11 to 2026-09-15.

Original reporting
SEC EDGAR · Giordano Christopher Thomas
Published Sep 16, 2026, 1:38 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 2:02 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TENX
Neutral
high confidence
Mentioned
$TENX
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TENXNeutralLow
01

Why it matters

The CEO's modest purchase adds a slight positive tone but is unlikely to move the stock.

02

Market read

Minor insider buy; limited trading relevance.

03

What to watch

Potential upcoming clinical trial milestones not disclosed may influence insider activity.

Relevance 4/10Novelty 3/10Timing: post‑market filing on Sep 15, 2026

Background

Form 4 filings disclose insider trades; investors monitor them for signals of insider confidence.

Company-level read

Ticker impact

$TENXNeutralHigh confidence
Context

CEO Giordano Christopher Thomas bought 10,850 shares for $20,087, increasing his stake to 22,174 shares.

Expected impact

Minimal price movement expected; may provide slight bullish bias.

Evidence & confidence

The transaction is a primary Form 4 filing, but the dollar amount is trivial for a public company.

Market effects

Sector

No immediate sector impact; biotech sector unchanged.

Regional

Limited to US biotech investors.

Global

Insignificant on a global scale.

Counterpoint

What could challenge this read

The purchase could be a routine portfolio rebalancing rather than a confidence signal.

Key entities

  • Person
    Giordano Christopher Thomas

    CEO of Tenax Therapeutics, Inc.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TENX insider trading history →

Related articles

SEP 4
$TENXMedAI 8/10

Tenax (TENX) Found a 26.3-Meter Benefit in a Prespecified Subgroup After LEVEL Missed Its Primary Endpoint. Is Another Phase 3 Trial Viable?

Tenax Therapeutics (TENX) reported that its Phase 3 LEVEL trial for TNX-103 missed primary endpoints but showed a 26.3-meter benefit in a prespecified subgroup of patients with severe baseline impairment. The company has $118.0 million in cash and plans to seek regulatory input for an enriched LEVEL-2 trial. Safety data was comparable between treatment and placebo groups.

insidermonkey.com2 min
AUG 31
$TENXHighAI 9/10

Why is Tenax Therapeutics stock volatile today?

Tenax Therapeutics (TENX) stock rose 3.8% in pre-market trading after presenting additional Phase 3 trial data at the European Society of Cardiology Congress. The data showed favorable treatment effects for TNX-103 in patients with severe pulmonary hypertension due to heart failure. Several Wall Street firms initiated coverage with Buy ratings and price targets of $35-$40. The company has $118 million in cash, providing a runway through Q2 2028.

investing.com2 min
AUG 29
$TENXMedAI 8/10

Tenax Therapeutics Presents Additional Phase 3 LEVEL Data Showing TNX-103 Benefits in PH-HFpEF Patients With Lower Baseline Walk Distance

Tenax Therapeutics (TENX) presented additional Phase 3 LEVEL trial data showing TNX-103 improved 6MWD, NT-proBNP, and RVSP in PH-HFpEF patients with lower baseline walk distance. The company plans to enrich the LEVEL-2 population based on these results. TNX-103 showed a 26.3m 6MWD improvement, 47% NT-proBNP reduction, and 4.9 mmHg RVSP reduction vs. placebo in this subgroup.

quiverquant.com3 min
AUG 29
$TENXMedAI 8/10

Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026

Tenax Therapeutics presented Phase 3 LEVEL trial results at ESC Congress 2026. TNX-103 showed significant improvements in patients with PH-HFpEF and baseline 6MWD below 333 meters, including a 26.3m walk distance improvement, 47% NT-proBNP reduction, and 4.9 mmHg RVSP reduction. The company plans to enrich the population for the next study.

finance.yahoo.com2 min